Media Coverage

At the ongoing ASM Microbe 2025, Meghan Starolis, PhD, senior science director of Infectious Diseases at the Quest Diagnostics’ Nichols Institute discussed her presentation, Conquering Antiviral Drug Resistance Via Novel Antivirals & New Testing Methods for Drug Resistance, which looked at genotypic and phenotypic testing and some of the benefits and challenges for each.

Quest Diagnostics will work on a blood test for cancer risk it says may help identify people who could benefit from more frequent screenings using technology developed at the MD Anderson Cancer Center. Dubbed the multi-cancer stratification test, or MCaST, Quest said it has licensed the center’s liquid chromatography and mass spectrometry approach to help build its own offering, which will aim to capture protein biomarkers circulating in the bloodstream that are associated with elevated risks for several different tumors.

Alex Louis, senior vice president of enterprise operations and operational excellence at Quest Diagnostics, shares more on how thoughtful planning is essential for successful automation implementation as clinical labs face growing pressure. Clinical laboratories in the US have long operated under significant pressure and challenges, and these have only intensified in recent times. Many laboratory leaders are now facing issues around workflow, staffing, and productivity. Improving the patient and customer experience is also a growing concern, so how can clinical laboratory leaders address these challenges quickly and smoothly?

Although nearly half of Americans know their streaming platform passwords by heart, only 19% are aware of what their cholesterol score is, according to new data from Quest Diagnostics. As part of its second “Know Your Health” survey, the Secaucus-based testing provider explored what perceptions and priorities adults have for their well-being in 2025. After surveying nearly 2,100 individuals, Quest found that 92% of respondents want to take a more active role in their health care journey. However, many said they face obstacles to receiving care, their doctors do not focus enough on preventive care discussions or have gaps in knowledge on important personal health information.

A new report reveals oncologists are seeing more advanced cancer cases due to screening barriers and are concerned current tests aren’t effective enough for early detection of recurrence. Takeaways: Screening barriers are seen as the leading cause of late-stage cancer diagnoses; Oncologists express concern that current monitoring tools may not detect cancer recurrence early; ctDNA MRD tests, like Quest’s new Haystack MRD, show promise in improving post-treatment cancer surveillance.